ALL vs ALLO · P/E 4.9, $56.89B cap vs rev $22.0K
The Allstate Corporation (ALL) versus Allogene Therapeutics Inc (ALLO) — a side-by-side from cached financials, not a winner call.
The Allstate Corporation (ALL) is a insurance - property & casualty company listed on US.
Allogene Therapeutics Inc (ALLO) is a biotechnology company listed on US.
ALL does not have a complete income-statement cache yet.
Latest reported ALLO revenue for 2024-12-31 was $22.0K. Net income was -$257.6M. Revenue was down 76.8% from 2023-12-31 to 2024-12-31. ALLO currently screens at market cap $258.1M.
ALL currently screens at market cap $56.89B and trailing P/E 4.9. ALLO currently screens at market cap $258.1M.
Not investment advice. Open the ALL and ALLO stock pages for the full models.
Not investment advice.